AnalytiXIN has launched a consortium designed to give Indiana researchers better access to health care data—potentially ...
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
We recently compiled a list of the Jim Cramer Recently Discussed These 17 Stocks And Chinese Hackers. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands ...
In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Is Eli Lilly a good stock to buy on the dip? On Jan. 14, CEO David Ricks told investors that 2024 sales would come in at ...
We recently published a list of Jim Cramer Discussed These 18 Stocks As Inflation Dropped. In this article, we are going to ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...
Omvoh (mirikizumab-mrkz) for moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for ...
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...
Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the ...
We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are ...
Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.